Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

General Electric Co GE

General Electric Company, doing business as GE Aerospace, is a global aerospace propulsion, services, and systems company. The Company provides jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. Its portfolio of brands includes Avio Aero, Unison, GE Additive and Dowty Propellers. Avio Aero is a GE Aerospace business which operates in the design, manufacturing, and maintenance of civil and military aeronautics subsystems and systems. Dowty Propellers manufactures integrated propeller systems, which are used in applications that range from regional airliners and military airlifters to marine hovercraft. GE Additive offers a suite of products for additive manufacturing. Unison builds advanced gas turbine components and electrical and mechanical systems throughout the world. Its services include TrueChoice commercial services, TRUEngine, on wing support, regional and business aviation, and test services.


NYSE:GE - Post by User

Post by SophiaBrownon Feb 04, 2022 2:01am
103 Views
Post# 34396100

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in the video above!
<< Previous
Bullboard Posts
Next >>